Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s DOI Creative Commons
Linjie Li, Pu Han,

Baihan Huang

et al.

Cell Discovery, Journal Year: 2022, Volume and Issue: 8(1)

Published: July 12, 2022

The Omicron variant of SARS-CoV-2 carries multiple unusual mutations, particularly in the receptor-binding domain (RBD) spike (S) protein. Moreover, host-adapting such as residues 493, 498, and 501, were also observed RBD, which indicates that it is necessary to evaluate interspecies transmission risk variant. Herein, we evaluated recognition BA.1 Delta RBDs by 27 ACE2 orthologs, including humans. We found expanded its receptor binding spectra palm-civet, rodents, more bats (least horseshoe bat greater bat) lesser hedgehog tenrec. Additionally, determined cryo-electron microscopy (cryo-EM) structure S protein complexed with mouse (mACE2) crystal RBD palm-civet (cvACE2). Several key for host range have been identified. These results suggest surveillance should be enhanced on broader-species prevent spillover expansion reservoir hosts a prolonged pandemic.

Language: Английский

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2 DOI Creative Commons
Pengcheng Han, Linjie Li, Sheng Liu

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(4), P. 630 - 640.e10

Published: Jan. 6, 2022

Language: Английский

Citations

455
Therapeutic strategies for COVID-19: progress and lessons learned DOI Open Access
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley

et al.

Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 22(6), P. 449 - 475

Published: April 19, 2023

Language: Английский

Citations

411
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies DOI Open Access
MacGregor Cox, Thomas P. Peacock, William T. Harvey

et al.

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: 21(2), P. 112 - 124

Published: Oct. 28, 2022

Language: Английский

Citations

267
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults DOI Open Access
Lianpan Dai,

Lidong Gao,

Lifeng Tao

et al.

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(22), P. 2097 - 2111

Published: May 4, 2022

The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with acceptable side-effect profile, immunogenic in adults phase 1 clinical trials.

Language: Английский

Citations

226
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events DOI Creative Commons
Junxian Ou, Wendong Lan,

Xiaowei Wu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: April 26, 2022

Abstract The current pandemic of COVID-19 is fueled by more infectious emergent Omicron variants. Ongoing concerns variants include possible recombinants, as genome recombination an important evolutionary mechanism for the emergence and re-emergence human viral pathogens. In this study, we identified diverse events between two major subvariants (BA.1 BA.2) other concern (VOCs) interest (VOIs), suggesting that co-infection subsequent play roles in ongoing evolution SARS-CoV-2. Through scanning high-quality completed spike gene sequences, 18 core mutations BA.1 (frequency >99%) 27 BA.2 (nine than BA.1) were identified, which 15 are specific to Omicron. share nine common amino acid (three protein with most VOCs, a origin from these VOCs. There three Alpha-related BA.2, phylogenetically closer Alpha Revertant found some dominant >95%) BA.1. Most notably, multiple characteristic Delta have been also “Deltacron”-like Variants isolated since November 11, 2021 South Africa, implies occurring Monitoring evolving SARS-CoV-2 genomes especially critically recognition abrupt changes attributes including its epitopes may call vaccine modifications.

Language: Английский

Citations

190
Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis DOI Open Access
Yang Pan, Liang Wang, Zhaomin Feng

et al.

The Lancet, Journal Year: 2023, Volume and Issue: 401(10377), P. 664 - 672

Published: Feb. 1, 2023

Language: Английский

Citations

172
Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant DOI Open Access
Xin Zhao, Dedong Li,

Wenjing Ruan

et al.

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(9), P. 894 - 896

Published: Jan. 26, 2022

A list of the investigators in MEDLEY Study Group is provided Section S1 Supplementary Appendix.A complete authors available with full text this letter at NEJM.org.The data sets generated or analyzed

Language: Английский

Citations

109
High-performance multifunctional electrospun fibrous air filter for personal protection: A review DOI
Zungui Shao, Huatan Chen, Qingfeng Wang

et al.

Separation and Purification Technology, Journal Year: 2022, Volume and Issue: 302, P. 122175 - 122175

Published: Sept. 22, 2022

Language: Английский

Citations

91
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates DOI Creative Commons

Yaling An,

Shihua Li,

Xiyue Jin

et al.

Emerging Microbes & Infections, Journal Year: 2022, Volume and Issue: 11(1), P. 1058 - 1071

Published: March 21, 2022

Safe, efficacious, and deployable vaccines are urgently needed to control COVID-19 in the large-scale vaccination campaigns. We report here preclinical studies of an approved protein subunit vaccine against COVID-19, ZF2001, which contains tandem-repeat dimeric receptor-binding domain (RBD) with alum-based adjuvant. assessed immunogenicity efficacy both mice non-human primates (NHPs). ZF2001 induced high levels RBD-binding SARS-CoV-2 neutralizing antibody primates, elicited balanced TH1/TH2 cellular responses NHPs. Two doses protected Ad-hACE2-transduced infection, as detected by reduced viral RNA relieved lung injuries. In NHPs, either 25 μg or 50 prevented infection lung, trachea, bronchi, milder lesions. No evidence disease enhancement was observed animal models. has been for emergency use China, Uzbekistan, Indonesia, Columbia. The safety, immunogenicity, protection NHPs found this study consistent results human clinical trials.

Language: Английский

Citations

81
An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB DOI Creative Commons

Qingwen He,

Lili Wu, Zepeng Xu

et al.

Cell Reports Medicine, Journal Year: 2023, Volume and Issue: 4(4), P. 100991 - 100991

Published: March 21, 2023

Emerging Omicron sub-variants are causing global concerns, and their immune evasion should be monitored continuously. We previously evaluated the escape of BA.1, BA.1.1, BA.2, BA.3 from an atlas 50 monoclonal antibodies (mAbs), covering seven epitope classes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD). Here, we update totally 77 mAbs against emerging including BQ.1.1 XBB find that BA.4/5, BQ.1.1, display further evasion. Besides, investigation into correlation binding neutralization reveals important role antigenic conformation in mAb functioning. Moreover, complex structures BA.2 RBD/BD-604/S304 BA.4/5 RBD/BD-604/S304/S309 elucidate molecular mechanism antibody by these sub-variants. By focusing on identified broadly potent mAbs, a general hotspot RBD, which could guide design vaccines calls for new broad-spectrum countermeasures COVID-19.

Language: Английский

Citations

67